Chimeric antigen receptor (CAR) T cell therapy is a therapeutic option for a variety of blood cancers but is ineffective at treating solid tumors and could cause inflammation and neurotoxicity. To overcome these barriers, scientists attach CARs to other immune cells. Unlike CAR T cells, CAR macrophages efficiently penetrate solid tumors, while CAR invariant natural killer T (iNKT) cells reduce the risk of hyperinflammation. In this webinar, Julie O’Neal will talk about using CAR iNKT cells as an alternative approach to treating multiple myeloma, while Quanyin Hu will discuss a novel method for generating CAR macrophages to prevent glioblastoma relapse in humanized mouse models.
Topics to be covered
- CAR iNKT cells as an alternative to CAR T cells for multiple myeloma treatment
- Engineering CAR macrophages in situ for glioblastoma cell therapy
Monday, December 18th, 2023 | 2:00 PM - 3:30 PM Eastern Time
This webinar will be available to view live and on demand.
Julie O’Neal, PhD
Washington University in St. Louis
Quanyin Hu, PhD
University of Wisconsin-Madison